Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
A Six-Week, Randomized, Double-Blind, Parallel Group Extension Study To Evaluate The
Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020 Compared To
Risperidone, In Schizophrenic Patients Previously Treated In Study Bl-1020 Iib For A Maximum
Of Six Weeks With Bl-1020 (High Dose, Low Dose), Risperidone Or Placebo